Comparison of United Kingdom (UK) and United States (U.S.) hypertension treatment status, physical activity and prospective mortality risk

Chenna Wang[1,2], Raaj K. Biswas[1, 3], Nicholas A. Koemel[1, 4], Matthew N. Ahmadi[1, 4]

[1]Mackenzie Wearables Research Hub, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia

[2]Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[3]School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia

[4]Turner Institute for Brain and Mental Health, Monash University, Victoria, Australia

Corresponding author:

Chenna Wang

Address for correspondence:

Concord Medical Education Centre, Concord Repatriation General Hospital, Concord West, New South Wales, Australia.

Email address:

cwan3359@uni.sydney.edu.au

Clinical trial number: not applicable

ABSTRACT

Background: The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline lowered diagnostic threshold for hypertension, encouraging earlier treatment initiation in the U.S. compared to UK, where the National Institute for Health and Care Excellence (NICE) guideline recommends higher thresholds. No comparative study evaluating how different hypertension guidelines and physical activity are jointly associated with mortality outcomes in two countries.

Aims: This study compared hypertension prevalence, treatment uptake, blood pressure (BP) levels, and mortality between the UK Biobank (UKBB) and the U.S. National Health and Nutrition Examination Survey (NHANES). We evaluated whether moderate-to-vigorous physical activity (MVPA) modifies mortality risk among different hypertension subgroups (normotensive, medicated hypertension, and unmedicated hypertension).

Methods: We harmonized demographic, biomarker, lifestyle, and accelerometer data from UKBB (n=63,452) and NHANES (n=7,397). Comprehensive weighting methods were applied in both cohorts. Accelerometry data was classified using a validated two-stage machine learning Random Forest algorithm. Associations between MVPA and all-cause mortality were examined with restricted cubic spline regression and visualized using Kaplan-Meier survival curves.

Results: NHANES showed a higher proportion of treated hypertension (29.9%) and lower average blood pressure (SBP/DBP: 122.2/70.7 mmHg) compared to UKBB (11.7% treated; SBP/DBP: 136.0/81.3 mmHg). Despite lower BP levels, cardiovascular mortality was higher in UKBB (10.3 per 10,000 person-years) compared to NHANES (4.0 per 10,000 person-years). In both cohorts, greater MVPA was linked to lower mortality risk, with the strongest association observed among medicated hypertensives. Notably, NHANES participants with treated hypertension and low MVPA (<10.7 minutes/day) experienced a steeper survival decline, falling to 74% by year 8, compared to 91% in normotensives and 79% in untreated hypertensives.

Conclusion: Despite higher treatment prevalence and lower average BP levels in NHANES, mortality remained higher compared with UKBB, suggesting that differences in mortality patterns may relate to broader cardiometabolic profiles and PA patterns beyond pharmacological management alone. Across both cohorts, higher levels of MVPA were associated with lower all-cause mortality, with the strongest associations were observed among individuals with medicated hypertension.

Introduction

Hypertension is a leading modifiable risk factors for premature cardiovascular mortality and long-term disability worldwide, affecting an estimated 1.39 billion adults worldwide [1-3]. Elevated BP is consistently associated with increased mortality risk from ischemic heart disease and stroke [2, 4]. Effective BP control is therefore essential to alleviate the global cardiovascular disease (CVD) burden.

However, definitions of hypertension differ across national guidelines, influencing both prevalence estimates and treatment strategies. The 2017 ACC/AHA guideline lowered the diagnostic threshold for hypertension to BP ≥130/80 mm Hg, advocating earlier initiation of pharmacologic treatment [5]. By contrast, the UK's NICE guideline maintains a higher threshold of BP ≥140/90 mm Hg, resulting in more conservative management practices [6]. These divergent thresholds raise critical questions regarding their respective impacts on hypertension detection, treatment uptake, and long-term cardiovascular outcomes. Evidence from the ESPRIT trial, shows that while intensive systolic blood pressure (SBP) lowering (<120 mm Hg) does not reduce total stroke incidence over 3.4 years, it can halve the risk of haemorrhagic stroke after about one year of treatment [7], underscoring how the benefits of tighter control depend on stroke subtype, patient characteristics, and the duration of exposure.

Physical activity (PA) has been widely recognized as a key nonpharmacological component in hypertension management. Regular PA lowers BP through improvements in vascular function and autonomic regulation, effects that tend to be more pronounced in people with hypertension [8-11]. Combining regular PA with pharmacologic treatment produces synergistic benefits, substantially lowering cardiovascular risk [9]. Despite these known relationships, a cross-national accelerometer study suggests that Americans, particularly those over age 50, are markedly less active than UK adults [12]. These findings suggest important cross-national differences in PA patterns. Despite clear evidence supporting early intervention and regular PA for hypertension management, it remains

unclear to what extent differences in national hypertension guidelines and PA patterns contribute to cardiovascular outcomes.

Compounding these differences, evidence indicates that cardiovascular mortality rates in the U.S. are substantially higher than those observed in other high-income countries, such as the UK [13, 14]. Taken together, these findings indicate that lower treatment thresholds in the U.S. have not necessarily corresponded with better cardiovascular outcomes. This pattern may reflect broader differences in cardiometabolic risk profiles and PA patterns.

This study uses data from two large, population-based cohorts, UKBB and NHANES, to compare hypertension prevalence, treatment patterns, and mortality under unified hypertension criteria. The study aims to explore whether accelerometer-measured PA levels modify the association between hypertension status and mortality within each cohort.

Methods

Study Design and Data Sources

Our study utilizing existing data from two well-established population-based cohorts: UKBB and NHANES [15-18]. These datasets include detailed demographic, behavioural, and clinical information, making them well-suited to evaluate how national hypertension guidelines and PA patterns influence mortality.

UKBB is a large, population-based cohort study established to investigate factors contributing to major diseases in middle-aged and older adults. It recruited 500,000 adults aged 40 to 69 years during 2006–2010 [16, 19]. UKBB data are linked to longitudinal mortality records through NHS Digital for participants in England and Wales, and through the NHS Central Register for participants in Scotland [20]. Wearables-based PA data were collected from a subset of 103,617 participants, each wearing triaxial accelerometers (Axivity AX3) on the wrist continuously for seven days at a sampling frequency of 100Hz [16, 21].

NHANES is a recurring national survey conducted by the U.S. Centres for Disease Control and Prevention (CDC) to assess the health and nutritional status of the non-institutionalized civilian population. In addition to cross-sectional data, NHANES is linked to longitudinal mortality follow-up through the National Death Index (NDI) [22]. The linked mortality files provide detailed individual-level time-to-event data, including date and cause of death, duration of follow-up, and mortality status. During the 2011-2014 cycles, a subsample of participants wore triaxial accelerometers (ActiGraph GT3X+) on wrist for seven consecutive days, recording data at 80 Hz sampling frequency [17, 23].

Eligibility Criteria and Data Extraction

We included participants aged 20 years or older if they have valid BP measurements, complete accelerometer data, and no missing values for key exposure and outcome variables. We conducted data harmonisation to align variable definitions and ensure consistency between UKBB and NHANES. We standardized variables using consistent definitions, measurement units, and clinically relevant cut-offs across cohorts. PA data derived from accelerometry was classified using a two-stage machine learning Random Forest algorithm, validated in prior studies [24-30]. In the first stage, 10-second windows were assigned to one of four activity classes (sedentary, standing utilitarian movements, walking activities, or running/high energetic activities). They were then mapped to sedentary, light (<100 mg), moderate (≥100 mg), or vigorous (≥400 mg) intensity levels [28-31]. The total duration of activity in each intensity band was aggregated across all valid wear days.

Before conducting mortality analyses, we applied further exclusions to improve the validity of risk estimates. Participants with incomplete mortality data were removed. We excluded participants who rated their health as poor or fair to minimise confounding by baseline frailty [28-30]. We excluded individuals who died within the first year of follow-up to reduce reverse causality risk [28-30].

Statistical Analysis Plan

105 Participants were categorised into three mutually exclusive hypertension groups based on the 2017
106 ACC/AHA guideline: (1) normotensive (SBP <130 mm Hg and DBP <80 mm Hg without BP-
107 lowering medications), (2) unmedicated hypertension (SBP ≥130 mm Hg or DBP ≥80 mm Hg
108 without BP-lowering medications), and (3) medicated hypertension (self-reported use of
109 antihypertensive medications) [5]. This classification was applied uniformly across both datasets,
110 facilitating direct comparisons between cohorts. We selected the 2017 ACC/AHA guideline because
111 it marked a paradigm shift in hypertension management in the U.S., while most other countries
112 maintain the long-standing benchmark of 140/90 mmHg [5, 32]. Despite different diagnostic thresholds,
113 there is strong international agreement that individuals at high atherosclerotic cardiovascular disease
114 (ASCVD) risk should aim for a BP target of <130/80 mmHg [33].
115 To mitigate the influence of extreme outliers, we winsorized moderate-to-vigorous physical activity
116 (MVPA) and measurements of SBP and DBP at the 2.5th and 97.5th percentiles [24, 26, 28-30]. We applied
117 robust weighting methods on both cohorts [34-36]. For UKBB, we applied inverse probability weighting
118 (IPW) based on recent work by van Alten et al. to correct for selection bias due to non-random
119 volunteer participation [37]. For NHANES, we incorporated sampling weights provided by the
120 National Centre for Health statistics (NCHS) to produce unbiased, population-level estimates
121 representative of the non-institutionalized U.S. civilian population [17].
122 We used Cox proportional hazards regression models to examine the relationship between MVPA
123 tertiles and all-cause mortality, separately within each hypertension group in both cohorts [29, 30, 38].
124 Covariates included age, sex, ethnicity, smoking status, alcohol intake, fruit and vegetable
125 consumption, educational attainment, previous CVD, family history of CVD, sleep duration, and
126 light physical activity (LPA) energy expenditure. We used forest plots to present the hazard ratios
127 (HRs) and 95% confidence intervals (CIs) for the intermediate and high MVPA tertiles relative to the
128 low MVPA reference group. Additionally, we generated covariate-adjusted Kaplan-Meier survival

curves to estimate survival probabilities across hypertension subgroups stratified by MVPA tertiles within each cohort.

All statistical analyses were conducted using R (version 4.4.1).

Subgroup and sensitivity analysis

To further validate the robustness of the primary findings, we conducted several subgroup and sensitivity analyses. First, given the differing age distributions between cohorts, we restricted the NHANES sample to adults aged 40–69 years to match the UKBB age range (Supplementary Figure 5–6). Second, we excluded participants with self-reported cardiovascular disease at baseline to minimise reverse causation (Supplementary Figure 7–8) [29, 30, 38]. To address the markedly higher baseline MVPA levels observed in UKBB compared with NHANES, we applied NHANES-derived MVPA tertile thresholds uniformly to both datasets (Supplementary Figure 9). This allowed direct comparison of survival outcomes at comparable MVPA levels. In addition, we conducted a sensitivity analysis using unweighted data from UKBB and NHANES to o evaluate whether the application of weighting methods in the primary analyses materially altered the observed survival patterns (Supplementary Figure 10).

Results

Participants demographics and characteristics

The weighted baseline demographic, behavioural, and clinical characteristics of participants from UKBB and NHANES are presented in Supplementary Table 1, while the unweighted characteristics are shown in Supplementary Table 2. The UKBB sample included 63,452 participants with a mean age of 58.2 years (SD = 8.3) and the NHANES sample consisted of 7,397 individuals, who were younger (mean age = 49.3 years, SD = 16.6). The ethnic composition also varied markedly: over 94% of UKBB participants identified as White, whereas NHANES included approximately 68% White, 11% Black, 4% Asian, and 16% Other (Supplementary Table 1; Supplementary Figure 1).

153 Lifestyle differences between cohorts were also evident. For example, PA patterns further
154 highlighted disparities: non-exercisers were more common in NHANES (46.4%) than in UKBB
155 (32.2%), and daily duration of MVPA was approximately double in UKBB (40.0 ± 25.2 min/day)
156 compared to NHANES (21.0 ± 17.4 min/day). Average daily alcohol intake was moderately higher
157 in NHANES (2.6 ± 2.2 units/day) compared to UKBB (1.9 ± 2.3 units/day). NHANES participants
158 had higher average waist circumference and body mass index (BMI) (100.2 cm and 29.3 kg/m^2,
159 respectively) relative to their UKBB counterparts (88.3 cm and 26.7 kg/m^2). Despite these indicators
160 of higher cardiometabolic risk in NHANES, SBP and DBP readings were paradoxically lower than
161 in UKBB. However, this apparent advantage in BP did not translate into survival benefit.
162 Cardiovascular mortality was more than three times higher in NHANES (2.3%) than in UKBB
163 (0.7%; Supplementary Table 1, Figure 1).
164 Across both cohorts, participants with medicated hypertension showed more adverse cardiometabolic
165 profiles than their unmedicated hypertensive counterparts. These individuals were older (UKBB:
166 63.9 vs. 58.6 years; NHANES: 60.8 vs. 50.5 years) and more metabolically compromised in terms of
167 HbA1C, HDL cholesterol, and triglycerides profiles. PA levels were also lower in this group. In
168 UKBB, mean MVPA was 33.4 minutes per day compared to 40.1 minutes among unmedicated
169 hypertensives. In NHANES, the gap was larger (13.8 vs. 22.9 minutes per day). Cardiovascular
170 mortality was highest among medicated hypertensives in both datasets (UKBB: 1.7%, NHANES:
171 5.1%, Figure 1). These trends suggest that lower PA levels may compound the residual risk despite
172 pharmacological treatment in medicated hypertension group.
173 ***BP Profiles and Treatment Prevalence***
174 The distribution of hypertension status under the 2017 ACC/AHA guideline differed substantially
175 between cohorts. In UKBB, 29.7% of participants were normotensive, 58.6% had unmedicated
176 hypertension, and 11.7% were receiving antihypertensive treatment. NHANES presented a different
177 pattern: 50.7% were normotensive, 19.4% had unmedicated hypertension, and 29.9% were treated

178 (Supplementary Figure 2). These differences suggest that U.S. adults were more likely to be
179 diagnosed and treated with antihypertensives, prompted by the lower treatment threshold.

180 ***All-cause mortality analysis***

181 **Cox analysis**

182 In multivariable-adjusted models, higher levels of MVPA were associated with lower all-cause
183 mortality risk in participants with medicated hypertension in UKBB when compared with the low
184 MVPA tertile. In NHANES, only the intermediate MVPA tertile was significantly associated with
185 lower mortality risk in medicated hypertension group (Supplementary Figure 4). Compared with the
186 low MVPA tertile, the high MVPA tertile was associated with a HR of 0.60 (95% CI 0.41–0.88) in
187 UKBB and 0.48 (95% CI 0.21–1.11) in NHANES, while the intermediate MVPA tertile was
188 associated with an HR of 0.69 (95% CI 0.49–0.98) in UKBB and 0.47 (95% CI 0.24–0.94) in
189 NHANES. In the unmedicated hypertension and normotensive subgroup, no statistically significant
190 associations were observed. Across most hypertension categories, point estimates generally indicated
191 lower mortality risk with higher MVPA, except in NHANES normotensives. Within NHANES,
192 medicated hypertension had relatively narrower CIs than the other two hypertension groups because
193 its total number of events (n = 260) was more than three times higher than in unmedicated
194 hypertension (n = 78) or normotensives (n = 78). In the NHANES medicated hypertension group, the
195 high MVPA tertile had a hazard ratio of 0.48 with a wider 95% CI of 0.21 to 1.11, likely due to
196 having fewer deaths events (n = 26), less than half the number in the intermediate tertile (n = 53).

197 **Kaplan–Meier survival curves**

198 Covariate-adjusted Kaplan–Meier survival curves were used to depict the cumulative incidence of
199 all-cause mortality over time across three hypertension groups, stratified by MVPA tertiles, in
200 UKBB and NHANES (Figure 2). In UKBB, survival probabilities remained above 90% throughout
201 the follow-up period across all MVPA strata, with minimal divergence between hypertension groups.
202 However, medicated hypertensive participants in the low MVPA tertile showed an earlier and

203 slightly steeper decline in survival probability compared to their normotensive and unmedicated
204 hypertensive counterparts, while higher MVPA tertiles showed convergence of survival curves
205 across hypertension groups.
206 In contrast, NHANES displayed clear separation of survival curves among hypertension groups,
207 most evident in participants in low MVPA tertile. Medicated hypertensives in this group showed a
208 steep decline in survival probability beginning early in the follow up period, reaching approximately
209 74% by year 8. This was substantially lower than normotensive and unmedicated hypertensive
210 groups, which retained higher probabilities closer to 91% and 79%, respectively. However, these
211 disparities were less evident in the intermediate and high MVPA strata, where survival curves for all
212 groups converged above 90% at year 8. These patterns suggest that higher MVPA are associated
213 with a lower mortality risk among individuals receiving antihypertensive treatment in both cohorts.
214 ***Sensitivity analysis***
215 Sensitivity analyses supported the robustness of the main findings. Aligning NHANES to the UKBB
216 age range and excluding participants with baseline cardiovascular disease did not materially alter the
217 associations between MVPA, hypertension status, and survival. Applying NHANES-derived MVPA
218 tertiles to both datasets provided clearer separation of survival curves at lower activity levels,
219 supporting the interpretation that increased MVPA mitigates mortality risks across hypertension
220 strata. In addition, analyses using unweighted data yielded Kaplan–Meier survival curves that were
221 largely consistent with those from the weighted primary analyses.
222 **Discussion**
223 ***Key findings***
224 The observed differences in hypertension status between UKBB and NHANES are closely linked to
225 distinct diagnostic and treatment criteria set by NICE and ACC/AHA guidelines. Specifically, the
226 ACC/AHA 2017 guideline defines hypertension at a lower threshold. It defines stage 1 hypertension
227 as SBP 130–139 mmHg or DBP 80–89 mmHg and recommends medication for adults within this

228 range if their estimated 10-year ASCVD risk is 10% or higher [5]. By contrast, treatment under NICE
229 typically starts at clinic BP ≥160/100 mmHg or ≥140/90 mmHg when significant cardiovascular risk
230 factors or target organ damage exist [6].
231 Despite lower mean BP among medicated hypertensive participants in NHANES (130.8/71.0
232 mmHg) compared with UKBB (147.2/85.8 mmHg), cardiovascular mortality remained higher in
233 NHANES (5.1% vs 1.7%). One potential explanation for the difference in cardiovascular mortality
234 rates involves differences in overall cardiometabolic health profiles. NHANES participants exhibited
235 poorer glycaemic control (5.7% vs. 5.4% in UKBB), lower HDL (52.9 mg/dL vs. 56.4 mg/dL), and
236 greater obesity burden as indicated by waist circumference (100.2 cm vs. 88.3 cm) and BMI (29.3
237 kg/m² vs. 26.7 kg/m²). Additionally, NHANES participants showed less favourable lifestyle
238 behaviours overall, particularly less daily MVPA (21.0 vs. 40.0 minutes/day). MVPA is a key
239 lifestyle factor due to its robust and well-established relationship with cardiovascular and all-cause
240 mortality [39-41]. MVPA can be objectively measured, allowing for precise evaluation of its health
241 impact. Therefore, this study focused on examining MVPA's role in mitigating mortality risk in
242 hypertension subgroups.
243 Higher MVPA levels were associated with lower all-cause mortality risk, especially among
244 medicated hypertensive participants in both cohorts. Compared with the low MVPA tertile, the
245 intermediate tertile was associated with a HR of 0.69 (95% CI: 0.49–0.98) in UKBB and 0.47 (95%
246 CI: 0.24–0.94) in NHANES. Covariate-adjusted Kaplan-Meier survival curves supported this, with
247 NHANES medicated hypertensive individuals in the lowest MVPA tertile (0.3–10.7 minutes/day)
248 experiencing significantly lower survival probabilities (~74% at year 8), compared to over 90%
249 survival in the intermediate (10.8–24.8 minutes/day) and high (≥24.8 minutes/day) MVPA tertiles.
250 These findings indicate that the association between MVPA and mortality varies by treatment status,
251 with the effect most evident among medicated hypertensive individuals. Regular PA modulates the
252 renin-angiotensin-aldosterone system, thereby improving BP control [10, 11]. PA also reduces

253 sympathetic tone, lowers peripheral vascular resistance, and enhances vascular function [42]. Together,
254 these mechanisms may help contextualize the observed associations between MVPA and lower
255 mortality among medicated hypertensive participants.
256 We observed no statistically significant association between MVPA and all-cause mortality among
257 normotensive participants. This observation aligns with prior findings that individuals who are
258 already healthy may experience smaller measurable benefits from increased PA compared with those
259 at higher risk [43]. To better understand this result, we examined the distribution of mortality causes in
260 this subgroup. Among all recorded deaths, only 15.9% were attributable to cardiovascular causes,
261 while 59.5% were attributed to cancer. This suggests that in normotensive individuals, cancer-related
262 mortality may predominate and dilute the overall association between MVPA and all-cause
263 mortality.
264 ***Clinical implication***
265 Our findings emphasize the insufficiency of antihypertensive medication alone in mitigating
266 mortality risk, particularly when other cardiometabolic risk factors or unhealthy lifestyle behaviours
267 persist. Recognizing this complexity, clinicians should adopt a comprehensive, multifactorial
268 approach that concurrently targets BP regulation, glycaemic and lipid optimisation, and sustained
269 lifestyle modifications.
270 Among modifiable risk factors, intensive lifestyle interventions can significantly lower
271 cardiovascular risk [44, 45]. Among the lifestyle factors, our study highlights the pronounced mortality
272 benefit of increased MVPA among medicated hypertensive patients. Regular PA not only lowers BP
273 [46, 47], but also is associated with lower risk of excessive weight gain, cardiovascular disease, and all-
274 cause mortality across diverse populations, including adults with preexisting chronic condition [48, 49].
275 Even modest increases in activity can produce significant health benefits among the least active
276 individuals [48]. Our findings reinforce this by showing that among medicated hypertensives in
277 NHANES, increasing MVPA from low to intermediate tertile was associated with an increase in 8-

278 year survival from approximately 74% to over 90%. Clinicians should routinely prescribe PA
279 alongside medications, supported by structured counselling and multidisciplinary teams [50].
280 U.S. adults exhibit a higher burden of cardiometabolic risk factors alongside wider socioeconomic
281 inequalities than their British counterparts [51, 52]. These disparities are partly driven by systemic
282 differences in healthcare structure and funding [53-55]. These system-level distinctions highlight that
283 optimal hypertension management requires not only clinical and behavioural interventions but also
284 policies that address affordability of primary care and social infrastructure. Among these public
285 health policies, this study draws particular attention to the social determinants that shape PA.
286 Individual efforts must be supported by community infrastructure and accessible facilities.
287 Neighbourhoods with connected street networks, accessible public transport, and plentiful parks led
288 to significantly higher PA levels across diverse cities [56]. Therefore, integrated, system-level
289 interventions connecting clinical recommendations to supportive community environments can more
290 effectively sustain behavioural changes and ultimately improve population health.
291 ***Strength and limitation***
292 Our study's strengths include the use of wearable devices to objectively measure PA. Extensive
293 evidence shows that self-reported measures provide only crude estimates of activity levels due to
294 recall and reporting biases, whereas wearables provide more objective estimates on intensity and
295 duration [57, 58]. Furthermore, we used aligned analytic strategies across two large, independent
296 population-based cohorts, facilitating direct comparison between UKBB and NHANES. The
297 availability of rich demographic, lifestyle, and clinical data in both cohorts enabled comprehensive
298 covariate adjustment, supporting more robust mortality analysis.
299 Our study also had several limitations. The one-week accelerometer measurement period might not
300 adequately capture long-term patterns, especially given that PA behaviours fluctuate across the life
301 course [59]. Second, in UKBB, biomarker and accelerometry data were obtained approximately five
302 years apart (baseline assessment in 2006–2010 and accelerometer measurements in 2013–2015). This

303 temporal gap introduces potential inconsistencies, as participants' hypertension profiles, medication
304 use, or PA patterns could have changed during this period. Third, we lacked information on
305 participants' adherence to prescribed medications, which may have influenced the observed
306 associations, especially when comparing medicated and unmedicated hypertension groups. Fourth,
307 BP readings were taken once and cannot confirm chronic hypertension status, distinguish between
308 controlled and uncontrolled hypertension within the medicated group, or assess individual
309 trajectories of BP over time. In addition, we noted wider CIs in NHANES compared with UKBB,
310 particularly in the unmedicated hypertension and normotensive subgroups. This pattern likely
311 reflects substantially fewer all-cause mortality events in NHANES compared with UKBB
312 (Supplementary Table 3), which diminished statistical power and amplified uncertainty in HR
313 estimates. Future studies should aim to obtain long-term accelerometry data, access general practice
314 records to assess medication adherence and repeated BP measurements, and include data from
315 broader settings, particularly from low- and middle-income countries and datasets with greater
316 volumes of mortality events.

317 **Conclusion**

318 In conclusion, our cross-cohort comparative analysis highlights that higher levels of MVPA were
319 consistently associated with lower all-cause mortality risks, with the most pronounced associations
320 observed among individuals already receiving antihypertensive treatment. Despite higher rates of
321 antihypertensive medication use and lower average BP readings in NHANES, cardiovascular
322 mortality remained higher compared to UKBB. These findings suggest that variation in mortality
323 patterns may reflect broader cardiometabolic profiles and PA patterns beyond pharmacological
324 hypertension treatment alone. The results provide context for public health initiatives and clinical
325 guidelines to consider how PA counselling and pharmacological management may jointly relate to
326 long-term mortality outcomes across different population settings.

List of abbreviations: ACC/AHA (American College of Cardiology/American Heart Association), ASCVD (atherosclerotic cardiovascular disease), BMI (body mass index), BP (blood pressure), CDC (Centers for Disease Control and Prevention), CI (confidence interval), CMD (cardiometabolic diseases), CVD (cardiovascular disease), DBP (diastolic blood pressure), HbA1c (hemoglobin A1c), HDL (high-density lipoprotein cholesterol), HR (hazard ratio), IPW (inverse probability weighting), LPA (light physical activity), MVPA (moderate-to-vigorous physical activity), NCHS (National Center for Health Statistics), NDI (National Death Index), NHANES (National Health and Nutrition Examination Survey), NHS (National Health Service), NICE (National Institute for Health and Care Excellence), PA (physical activity), RF (random forest), SBP (systolic blood pressure), SD (standard deviation), UK (United Kingdom), UKBB (UK Biobank), U.S. (United States).

Declaration

Ethic approval and consent to participate: In UKBB, ethical approval for data collection was obtained from the North West Multi-Centre Research Ethics Committee. The NHANES protocol was approved by the US NHANES institutional review board and National Center for Health Statistics Research ethics review board. All participants provided written informed consent.

Consent for publication: Not applicable.

Availability of data and materials: NHANES data are available at www.cdc.gov/nchs/nhis/index.htm, and data from UK Biobank are available on application at www.ukbiobank.ac.uk/register-apply.

Competing interests: We declare no competing interests.

Author's contributions: CW, RKB, NAK, and MNA were major contributors to the study design, data analysis, drafting of the manuscript, and manuscript revision. ES made substantial contributions

349 to the data analysis methodology, interpretation of the findings, and critical revision of the

350 manuscript. All authors read and approved the final manuscript.

351 References
352
353 1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and
354 injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic
355 analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2224-2260. 2012/12/19.
356 DOI: 10.1016/s0140-6736(12)61766-8.
357 2. Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood
358 Pressure of at Least 110 to 115 mm Hg, 1990-2015. *Jama* 2017; 317: 165-182. 2017/01/18. DOI:
359 10.1001/jama.2016.19043.
360 3. Mills KT, Stefanescu A and He J. The global epidemiology of hypertension. *Nat Rev Nephrol*
361 2020; 16: 223-237. 2020/02/07. DOI: 10.1038/s41581-019-0244-2.
362 4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to
363 vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
364 *Lancet* 2002; 360: 1903-1913. 2002/12/21. DOI: 10.1016/s0140-6736(02)11911-8.
365 5. Whelton PK, Carey RM, Aronow WS, et al. 2017
366 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,
367 detection, evaluation, and management of high blood pressure in adults: a report of the American
368 College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
369 *Journal of the American College of Cardiology* 2018; 71: e127-e248.
370 6. National Institute for Health and Care Excellence: Guidelines. *Hypertension in adults:*
371 *diagnosis and management*. London: National Institute for Health and Care Excellence (NICE)
372 Copyright © NICE 2023., 2023.
373 7. Li J, Lei L, Li Y, et al. Effect of Intensive Blood Pressure Control on Stroke: A Prespecified
374 Secondary Analysis of the ESPRIT Trial. *JACC* 2025.
375 8. Lesniak KT and Dubbert PM. Exercise and hypertension. *Curr Opin Cardiol* 2001; 16: 356-
376 359. 2001/11/13. DOI: 10.1097/00001573-200111000-00007.

377 9. Hou X, Yue S, Xu Z, et al. Joint Modifiable Risk Factor Control and Incident Stroke in
378 Hypertensive Patients. *J Clin Hypertens (Greenwich)* 2024; 26: 1274-1283. 2024/09/28 22:42. DOI:
379 10.1111/jch.14905.
380 10. Maris SA, Meyer KM, Murray G, et al. Physical Activity and the Acute Hemodynamic
381 Response to ACE Inhibition in Hypertension. *American Journal of Lifestyle Medicine* 2022; 16: 538-
382 545. DOI: 10.1177/1559827620935367.
383 11. Goessler K, Polito M and Cornelissen VA. Effect of exercise training on the renin-
384 angiotensin-aldosterone system in healthy individuals: a systematic review and meta-analysis.
385 *Hypertens Res* 2016; 39: 119-126. 2015/09/25. DOI: 10.1038/hr.2015.100.
386 12. Kapteyn A, Banks J, Hamer M, et al. What they say and what they do: comparing physical
387 activity across the USA, England and the Netherlands. *J Epidemiol Community Health* 2018; 72:
388 471-476. 2018/04/13. DOI: 10.1136/jech-2017-209703.
389 13. Acosta E, Mehta N, Myrskylä M, et al. Cardiovascular Mortality Gap Between the United
390 States and Other High Life Expectancy Countries in 2000-2016. *J Gerontol B Psychol Sci Soc Sci*
391 2022; 77: S148-s157. 2022/02/24. DOI: 10.1093/geronb/gbac032.
392 14. Pritchard C, Porter S, Rosenorn-Lanng E, et al. Mortality in the USA, the UK and Other
393 Western Countries, 1989–2015: What Is Wrong With the US? *International Journal of Health*
394 *Services* 2021; 51: 59-66. DOI: 10.1177/0020731420965130.
395 15. Allen N, Sudlow C, Downey P, et al. UK Biobank: Current status and what it means for
396 epidemiology. *Health Policy and Technology* 2012; 1: 123-126.
397 16. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying
398 the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; 12:
399 e1001779. 20150331. DOI: 10.1371/journal.pmed.1001779.
400 17. Statistics NCfH. NHANES Survey Methods and Analytic Guidelines. 2024.

401 18. Terry AL, Chiappa MM, McAllister J, et al. Plan and Operations of the National Health and
402 Nutrition Examination Survey, August 2021-August 2023. *Vital and Health statistics Ser 1,*
403 *Programs and Collection Procedures* 2024: 1-21.
404 19. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related
405 Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol*
406 2017; 186: 1026-1034. DOI: 10.1093/aje/kwx246.
407 20. Biobank U. Mortality data: linkage to death registries. 2023.
408 21. Doherty A, Jackson D, Hammerla N, et al. Large scale population assessment of physical
409 activity using wrist worn accelerometers: the UK biobank study. *PloS one* 2017; 12: e0169649.
410 22. Prevention CfDCa. NCHS Data Linked to NDI Mortality Files,
411 https://www.cdc.gov/nchs/data-linkage/mortality.htm (2024, accessed June 25th 2025).
412 23. Koffman L and Muschelli J. Minute level step counts and physical activity data from the
413 National Health and Nutrition Examination Survey (NHANES) 2011-2014.
414 24. Stamatakis E, Ahmadi MN, Gill JMR, et al. Association of wearable device-measured
415 vigorous intermittent lifestyle physical activity with mortality. *Nat Med* 2022; 28: 2521-2529.
416 20221208. DOI: 10.1038/s41591-022-02100-x.
417 25. Pavey TG, Gilson ND, Gomersall SR, et al. Field evaluation of a random forest activity
418 classifier for wrist-worn accelerometer data. *J Sci Med Sport* 2017; 20: 75-80. 20160623. DOI:
419 10.1016/j.jsams.2016.06.003.
420 26. Ahmadi MN, Clare PJ, Katzmarzyk PT, et al. Vigorous physical activity, incident heart
421 disease, and cancer: how little is enough? *Eur Heart J* 2022; 43: 4801-4814. DOI:
422 10.1093/eurheartj/ehac572.
423 27. Stamatakis E, Ahmadi MN, Friedenreich CM, et al. Vigorous Intermittent Lifestyle Physical
424 Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry
425 Study. *JAMA Oncol* 2023; 9: 1255-1259. DOI: 10.1001/jamaoncol.2023.1830.

426 28. Koemel NA, Ahmadi MN, Biswas RK, et al. Vigorous intermittent lifestyle physical activity
427 (VILPA) and mortality risk among US adults: a wearables-based national cohort study. *medRxiv*
428 2025: 2025.2008.2005.25333017. DOI: 10.1101/2025.08.05.25333017.
429 29. Stamatakis E, Koemel NA, Biswas RK, et al. Minimum and optimal combined variations in
430 sleep, physical activity, and nutrition in relation to all-cause mortality risk. *BMC Med* 2025; 23: 111.
431 20250226. DOI: 10.1186/s12916-024-03833-x.
432 30. Koemel NA, Ahmadi MN, Biswas RK, et al. Can incidental physical activity offset the
433 deleterious associations of sedentary behaviour with major adverse cardiovascular events? *Eur J*
434 *Prev Cardiol* 2025; 32: 77-85. DOI: 10.1093/eurjpc/zwae316.
435 31. Hildebrand M, VT VANH, Hansen BH, et al. Age group comparability of raw accelerometer
436 output from wrist- and hip-worn monitors. *Med Sci Sports Exerc* 2014; 46: 1816-1824. DOI:
437 10.1249/MSS.0000000000000289.
438 32. Vidal-Petiot E. Thresholds for Hypertension Definition, Treatment Initiation, and Treatment
439 Targets: Recent Guidelines at a Glance. *Circulation* 2022; 146: 805-807. DOI:
440 doi:10.1161/CIRCULATIONAHA.121.055177.
441 33. Vemu PL, Yang E and Ebinger JE. Moving Toward a Consensus: Comparison of the 2023
442 ESH and 2017 ACC/AHA Hypertension Guidelines. *JACC Adv* 2024; 3: 101230. 2024/09/17. DOI:
443 10.1016/j.jacadv.2024.101230.
444 34. Stamatakis E, Owen KB, Shepherd L, et al. Is Cohort Representativeness Passe?
445 Poststratified Associations of Lifestyle Risk Factors with Mortality in the UK Biobank.
446 *Epidemiology* 2021; 32: 179-188. 2021/01/26. DOI: 10.1097/EDE.0000000000001316.
447 35. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between
448 accelerometry measured physical activity and sedentary time and all cause mortality: systematic
449 review and harmonised meta-analysis. *BMJ* 2019; 366: l4570. 20190821. DOI: 10.1136/bmj.l4570.

450 36. Carlson SA, Fulton JE, Pratt M, et al. Inadequate physical activity and health care
451 expenditures in the United States. *Prog Cardiovasc Dis* 2015; 57: 315-323. 20140809. DOI:
452 10.1016/j.pcad.2014.08.002.
453 37. van Alten S, Domingue BW, Faul J, et al. Reweighting UK Biobank corrects for pervasive
454 selection bias due to volunteering. *Int J Epidemiol* 2024; 53 2024/05/08. DOI: 10.1093/ije/dyae054.
455 38. Koemel NA, Ahmadi MN, Biswas RK, et al. Vigorous intermittent lifestyle physical activity
456 (VILPA) and mortality risk among US adults: a wearables-based national cohort study. *medRxiv*
457 2025: 2025.2008. 2005.25333017.
458 39. Kraus WE, Powell KE, Haskell WL, et al. Physical Activity, All-Cause and Cardiovascular
459 Mortality, and Cardiovascular Disease. *Med Sci Sports Exerc* 2019; 51: 1270-1281. 2019/05/17.
460 DOI: 10.1249/mss.0000000000001939.
461 40. Bakker EA, Lee D-c, Hopman MT, et al. Dose–response association between moderate to
462 vigorous physical activity and incident morbidity and mortality for individuals with a different
463 cardiovascular health status: A cohort study among 142,493 adults from the Netherlands. *PLoS*
464 *medicine* 2021; 18: e1003845.
465 41. Lopez JPR, Gebel K, Chia D, et al. Associations of vigorous physical activity with all-cause,
466 cardiovascular and cancer mortality among 64 913 adults. *BMJ Open Sport & Exercise Medicine*
467 2019; 5.
468 42. Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position
469 stand. Exercise and hypertension. *Med Sci Sports Exerc* 2004; 36: 533-553. 2004/04/13. DOI:
470 10.1249/01.mss.0000115224.88514.3a.
471 43. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between
472 accelerometry measured physical activity and sedentary time and all cause mortality: systematic
473 review and harmonised meta-analysis. *bmj* 2019; 366.

474 44. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary
475 Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American
476 Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e596-e646.
477 DOI: doi:10.1161/CIR.0000000000000678.
478 45. Ornish D, Scherwitz LW, Billings JH, et al. Intensive Lifestyle Changes for Reversal of
479 Coronary Heart Disease. *JAMA* 1998; 280: 2001-2007. DOI: 10.1001/jama.280.23.2001.
480 46. Pescatello LS, Franklin BA, Fagard R, et al. Exercise and Hypertension. *Medicine & Science*
481 *in Sports & Exercise* 2004; 36: 533-553. DOI: 10.1249/01.Mss.0000115224.88514.3a.
482 47. Cornelissen VA and Smart NA. Exercise training for blood pressure: a systematic review and
483 meta-analysis. *J Am Heart Assoc* 2013; 2: e004473. 2013/03/26. DOI: 10.1161/jaha.112.004473.
484 48. Health UDo and Services H. 2018 Physical activity guidelines advisory committee scientific
485 report. 2018: Part F. Chapter 6. .
486 49. Powell KE, King AC, Buchner DM, et al. The Scientific Foundation for the Physical Activity
487 Guidelines for Americans, 2nd Edition. *Journal of Physical Activity and Health* 2019; 16: 1-11. DOI:
488 10.1123/jpah.2018-0618.
489 50. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to Promote Physical Activity
490 and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults. *Circulation*
491 2010; 122: 406-441. DOI: doi:10.1161/CIR.0b013e3181e8edf1.
492 51. Bridger Staatz C, Gutin I, Tilstra A, et al. Midlife health in Britain and the United States: a
493 comparison of two nationally representative cohorts. *International Journal of Epidemiology* 2024;
494 53. DOI: 10.1093/ije/dyae127.
495 52. Banks J, Marmot M, Oldfield Z, et al. Disease and Disadvantage in the United States and in
496 England. *JAMA* 2006; 295: 2037-2045. DOI: 10.1001/jama.295.17.2037.

497 53. Mainous AG, 3rd, Diaz VA, Saxena S, et al. Diabetes management in the USA and England:
498 comparative analysis of national surveys. *J R Soc Med* 2006; 99: 463-469. 2006/09/02. DOI:
499 10.1177/014107680609900918.
500 54. Desai M, Rachet B, Coleman MP, et al. Two countries divided by a common language:
501 health systems in the UK and USA. *J R Soc Med* 2010; 103: 283-287. 2010/07/03. DOI:
502 10.1258/jrsm.2010.100126.
503 55. Papanicolas I, Mossialos E, Gundersen A, et al. Performance of UK National Health Service
504 compared with other high income countries: observational study. *BMJ* 2019; 367: l6326. DOI:
505 10.1136/bmj.l6326.
506 56. Sallis JF, Cerin E, Conway TL, et al. Physical activity in relation to urban environments in 14
507 cities worldwide: a cross-sectional study. *The Lancet* 2016; 387: 2207-2217. DOI: 10.1016/S0140-
508 6736(15)01284-2.
509 57. Prince SA, Adamo KB, Hamel ME, et al. A comparison of direct versus self-report measures
510 for assessing physical activity in adults: a systematic review. *Int J Behav Nutr Phys Act* 2008; 5: 56.
511 20081106. DOI: 10.1186/1479-5868-5-56.
512 58. Dyrstad SM, Hansen BH, Holme IM, et al. Comparison of self-reported versus
513 accelerometer-measured physical activity. *Med Sci Sports Exerc* 2014; 46: 99-106. 2013/06/25. DOI:
514 10.1249/MSS.0b013e3182a0595f.
515 59. Gropper H, John JM, Sudeck G, et al. The impact of life events and transitions on physical
516 activity: A scoping review. *PloS one* 2020; 15: e0234794.
517

Figure 1: Weighted distribution of systolic blood pressure, diastolic blood pressure, and cardiovascular mortality by hypertension groups in UK Biobank and NHANES



Box plots show median SBP and DBP values across normotensive, unmedicated hypertensive, and medicated hypertensive subgroups in UKBB and NAHNES, including adults aged 20 years and older. Bar plots represent cardiovascular mortality rates within each hypertension subgroup.

Figure 2: Weighted Kaplan-Meier survival curves for all-cause mortality by hypertension groups stratified by moderate-to-vigorous physical activity tertiles in UKBB and NHANES



MVPA tertiles were defined using cohort-specific distributions of accelerometer-measured daily duration of MVPA (minutes/day). For UKBB: Low (5.50–24.71), Intermediate (24.72–45.89), and High (≥45.90). For NHANES: Low (0.29–10.72), Intermediate (10.73–24.78), and High (≥24.79). Analysis included participants aged 20 years and older in UKBB and NHANES.

Comparison of United Kingdom (UK) and United States (U.S.) hypertension treatment status, physical activity and prospective mortality risk

Supplementary material

Table of contents

Page	Item
3	**Supplementary Figure 1**: Flow diagram of participants in the study
4	**Supplementary Figure 2**: Weighted distribution of demographic factors by hypertension groups in UK Biobank and NHANES
5	**Supplementary Figure 3**: Weighted distribution of hypertension groups in UK Biobank and NHANES under the 2017 American College of Cardiology/American Heart Association guideline
6	**Supplementary Figure 4**: Hazard ratios for all-cause mortality across moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES
7	**Supplementary Figure 5**: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles: primary analysis and sensitivity analysis restricted to adults aged 40–69 in NHANES
8	**Supplementary Figure 6**: Weighted distribution of blood pressure and cardiovascular mortality by hypertension groups in UK Biobank and NHANES: sensitivity analysis restricted to adults aged 40–69 years in NHANES
9	**Supplementary Figure 7:** Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles in UK Biobank, primary analysis and sensitivity analysis excluding participants with prior cardiovascular disease
10	**Supplementary Figure 8:** Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical

	activity tertiles: primary and sensitivity analyses excluding participants with prior cardiovascular disease in NHANES
11	**Supplementary Figure 9:** Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by NHANES-specific moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES
12	**Supplementary Figure 10:** Unweighted Kaplan-Meier survival curves for all-cause mortality by hypertension groups stratified by moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES
13	**Supplementary Table 1**: Weighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES
17	**Supplementary Table 2**: Unweighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES
21	**Supplementary Table 3**: Number of all-cause mortality events by moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES

Supplementary Figure 1: Flow diagram of participants in the study



Supplementary Figure 2: Weighted distribution of demographic factors by hypertension groups in UK Biobank and NHANES



Box plots display median age and interquartile ranges, while bar plots show sex and ethnic group proportions across hypertension subgroups within UKBB and NHANES.

Supplementary Figure 3: Weighted distribution of hypertension groups in UK Biobank and NHANES under the 2017 American College of Cardiology/American Heart Association guideline



Bar plots depict the percentage of normotensive, unmedicated hypertensive, and medicated hypertensive participants in each cohort. Values are weighted.

Supplementary Figure 4: Hazard ratios for all-cause mortality across moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES



Each subgroup was stratified into MVPA tertiles (low, medium, high), with the low MVPA tertile serving as the reference category (HR = 1.00). HRs are presented with 95% confidence intervals. Models adjusted for age, sex, smoking status, fruit and vegetables intake, previous CVD, family history of CVD, sleep duration, educational attainment, alcohol consumption, ethnicity, and light physical activity energy expenditure.

Supplementary Figure 5: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles: primary analysis and sensitivity analysis restricted to adults aged 40–69 in NHANES



The primary analysis includes all eligible NHANES participants aged ≥20 years. The sensitivity analysis is restricted to adults aged 40–69 years, to align with the age range of participants in UKBB.

Supplementary Figure 6: Weighted distribution of blood pressure and cardiovascular mortality by hypertension groups in UK Biobank and NHANES: sensitivity analysis restricted to adults aged 40–69 years in NHANES



The primary analysis includes all eligible NHANES participants aged ≥20 years. The sensitivity analysis is restricted to adults aged 40–69 years, to align with the age range of participants in UKBB.

Supplementary Figure 7: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles in UK Biobank: primary analysis and sensitivity analysis excluding participants with prior cardiovascular disease



Supplementary Figure 8: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by moderate-to-vigorous physical activity tertiles: primary and sensitivity analyses excluding participants with prior cardiovascular disease in NHANES



Supplementary Figure 9: Weighted Kaplan–Meier survival curves for all-cause mortality by hypertension status stratified by NHANES-specific moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES



MVPA tertiles were defined using the NHANES distribution as follows: Low (0.29–10.72 min/day), Intermediate (10.73–24.78 min/day), and High (≥24.79 min/day). These thresholds were applied uniformly to both UKBB and NHANES.

Supplementary Figure 10: Unweighted Kaplan-Meier survival curves for all-cause mortality by hypertension groups stratified by moderate-to-vigorous physical activity tertiles in UK Biobank and NHANES



The unweighted sensitivity analysis includes all eligible participants aged ≥20 years in both cohorts and was conducted to assess whether Kaplan-Meier survival curves were influenced by weighting approaches.

Supplementary Table 1: Weighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES

	Overall UKBB	*Normotensive UKBB*	*Unmedicated HTN UKBB*	*Medicated HTN UKBB*	*Overall NHANES*	*Normotensive NHANES*	*Unmedicated HTN NHANES*	*Medicated HTN NHANES*
n	53049	15750	31110	6190	157714415	79197815	30617498	47899102
Age, mean (s.d.), years	58.24 (8.26)	55.31 (7.42)	58.58 (8.18)	63.93 (7.29)	49.31 (16.58)	41.93 (14.71)	50.50 (15.28)	60.76 (13.26)
Female, n (%)	27888 (52.6)	10446 (66.3)	14668 (47.1)	2774 (44.8)	81057233 (51.4)	42524713 (53.7)	12576778 (41.1)	25955742 (54.2)
Ethnicity, n (%)								
White	50146 (94.5)	14800 (94.0)	29504 (94.8)	5841 (94.4)	107949339 (68.4)	52628154 (66.5)	20917441 (68.3)	34403744 (71.8)
Black	887 (1.7)	251 (1.6)	488 (1.6)	148 (2.4)	16984269 (10.8)	6604445 (8.3)	3604798 (11.8)	6775026 (14.1)
Asian	1301 (2.5)	420 (2.7)	743 (2.4)	138 (2.2)	6926901 (4.4)	4221495 (5.3)	1249162 (4.1)	1456244 (3.0)
Other	716 (1.3)	278 (1.8)	375 (1.2)	63 (1.0)	25853906 (16.4)	15743722 (19.9)	4846097 (15.8)	5264087 (11.0)
Smoking history, n (%)								

Never	30745 (58.0)	9532 (60.5)	18014 (57.9)	3200 (51.7)	80105586 (56.6)	46142249 (61.4)	15725290 (55.5)	18238046 (48.1)
Previous	17862 (33.7)	4768 (30.3)	10522 (33.8)	2572 (41.6)	35028853 (24.8)	14303349 (19.0)	7317600 (25.8)	13407905 (35.4)
Current	4442 (8.4)	1450 (9.2)	2575 (8.3)	418 (6.7)	26302250 (18.6)	14763827 (19.6)	5305744 (18.7)	6232680 (16.5)
Alcohol daily consumption, mean (s.d.)	1.93 (2.25)	1.53 (1.71)	2.08 (2.37)	2.18 (2.65)	2.57 (2.23)	2.61 (2.21)	2.64 (2.22)	2.44 (2.27)
Education, n (%)								
High school graduate, GED or equivalent	13702.4 (25.8)	4116.0 (26.1)	8068.1 (25.9)	1518.3 (24.5)	33127235.1 (21.0)	14907871.6 (18.8)	7270395.3 (23.7)	10948968.3 (22.9)
Some college or AA degree	10085.2 (19.0)	2627.2 (16.7)	6199.9 (19.9)	1258.2 (20.3)	50793895.5 (32.2)	25179272.6 (31.8)	9237213.9 (30.2)	16377409.0 (34.2)
College graduate	22327.1 (42.1)	7590.5 (48.2)	12688.6 (40.8)	2048.0 (33.1)	49859228.0 (31.6)	28494089.8 (36.0)	9656906.7 (31.5)	11708231.4 (24.5)
Other	6934.4 (13.1)	1416.2 (9.0)	4153.2 (13.4)	1365.0 (22.1)	23876102.5 (15.1)	10592293.8 (13.4)	4448313.5 (14.5)	8835495.3 (18.5)
Fruit and vegetable consumption,	7.77 (4.48)	7.83 (4.65)	7.68 (4.36)	8.07 (4.67)	4.76 (3.53)	4.84 (3.86)	4.67 (3.06)	4.68 (3.22)

mean (s.d.), servings/day								
Previous CVD, n(%)	3729.8 (7.0)	688.1 (4.4)	2123.7 (6.8)	918.0 (14.8)	14562762.3 (9.2)	2867626.7 (3.6)	1538512.5 (5.0)	10156623.1 (21.3)
Family history of CVD, n (%)	26826.5 (50.6)	7057.1 (44.8)	15907.7 (51.1)	3861.7 (62.4)	19830689.8 (12.8)	7972862.9 (10.3)	3208760.6 (10.7)	8649066.3 (18.4)
Non-exerciser, n (%)	17107.5 (32.2)	4303.3 (27.3)	10158.2 (32.7)	2645.9 (42.7)	73218637.2 (46.4)	31048363.9 (39.2)	14762375.2 (48.2)	27407898.1 (57.2)
Sleep, mean (s.d.), minutes/day	440.08 (91.78)	441.69 (96.80)	439.74 (90.59)	437.69 (84.22)	390.67 (125.14)	402.08 (119.73)	380.12 (127.52)	378.54 (130.58)
HbA1C, mean (s.d.), %	5.35 (0.51)	5.25 (0.38)	5.36 (0.52)	5.57 (0.67)	5.67 (0.98)	5.44 (0.73)	5.70 (1.04)	6.03 (1.18)
HDL, mean (s.d.), mg/dL	56.44 (14.45)	58.57 (14.36)	56.01 (14.37)	53.18 (14.29)	52.86 (15.82)	53.63 (15.14)	52.87 (18.13)	51.56 (15.27)
LDL, mean (s.d.), mg/dL	136.09 (32.18)	130.42 (30.07)	140.58 (32.09)	127.91 (33.87)	114.61 (35.50)	114.51 (33.06)	119.88 (36.35)	112.18 (38.43)
triglyceride, mean (s.d.), mg/dL	145.72 (87.33)	121.32 (70.88)	153.78 (91.03)	167.36 (92.81)	129.18 (116.30)	115.45 (128.78)	136.83 (92.45)	147.04 (102.59)
SBP, mean (s.d.), mmHg	136.02 (17.92)	117.29 (7.33)	143.28 (14.45)	147.20 (16.88)	122.23 (16.00)	112.54 (8.74)	133.80 (12.42)	130.84 (17.41)

DBP, mean (s.d.), mmHg	81.26 (10.12)	71.23 (5.06)	85.42 (8.41)	85.84 (9.68)	70.67 (10.76)	67.20 (7.87)	79.07 (10.03)	71.03 (12.23)
Waist circumference, mean (s.d.), cm	88.27 (13.09)	82.34 (11.14)	89.76 (12.65)	95.87 (13.81)	100.20 (16.11)	95.60 (14.58)	102.14 (16.01)	106.81 (16.12)
Body Mass Index, mean (s.d.), kg/m²	26.70 (4.59)	24.88 (3.69)	27.11 (4.49)	29.28 (5.35)	29.25 (6.82)	27.75 (5.92)	29.77 (6.92)	31.43 (7.49)
CVD mortality, n (%)	328.2 (0.7)	36.8 (0.2)	199.7 (0.7)	91.7 (1.7)	3634417.5 (2.3)	659032.3 (0.8)	515765.1 (1.7)	2459620.1 (5.1)
Daily MVPA duration, mean (s.d.), minutes/day	40.01 (25.23)	42.47 (25.31)	40.09 (25.24)	33.36 (23.76)	21.04 (17.37)	24.69 (17.38)	22.90 (17.28)	13.82 (15.05)

Abbreviations:
AA, Associate's degree;
GED, General Educational Development;
HDL, high-density lipoprotein cholesterol;
LDL, low-density lipoprotein cholesterol;

Supplementary Table 2: Unweighted baseline demographic, behavioural, and clinical characteristics of participants stratified by hypertension status in UK Biobank and NHANES

	Overall UKBB	*Normotensive UKBB*	*Unmedicated HTN UKBB*	*Medicated HTN UKBB*	*Overall NHANES*	*Normotensive NHANES*	*Unmedicated HTN NHANES*	*Medicated HTN NHANES*
n	63452	16814	37747	8891	7397	3445	1414	2538
Age, mean (s.d.), years	61.57 (7.86)	58.69 (7.80)	61.88 (7.72)	65.72 (6.33)	50.72 (17.28)	41.89 (15.26)	51.76 (15.88)	62.12 (13.31)
Female, n (%)	35790 (56.4)	11783 (70.1)	19850 (52.6)	4157 (46.8)	3749 (50.7)	1837 (53.3)	560 (39.6)	1352 (53.3)
Ethnicity, n (%)								
White	61597 (97.1)	16255 (96.7)	36741 (97.3)	8601 (96.7)	3118 (42.2)	1434 (41.6)	577 (40.8)	1107 (43.6)
Black	514 (0.8)	128 (0.8)	275 (0.7)	111 (1.2)	1719 (23.2)	584 (17.0)	360 (25.5)	775 (30.5)
Asian	675 (1.1)	203 (1.2)	374 (1.0)	98 (1.1)	796 (10.8)	472 (13.7)	144 (10.2)	180 (7.1)
Other	666 (1.0)	228 (1.4)	357 (0.9)	81 (0.9)	1764 (23.8)	955 (27.7)	333 (23.6)	476 (18.8)
Smoking history, n (%)								

Never	36444 (57.4)	10133 (60.3)	21709 (57.5)	4602 (51.8)	3685 (57.2)	1999 (61.7)	721 (56.0)	965 (50.3)
Previous	22795 (35.9)	5424 (32.3)	13563 (35.9)	3808 (42.8)	1503 (23.3)	582 (18.0)	294 (22.8)	627 (32.7)
Current	4213 (6.6)	1257 (7.5)	2475 (6.6)	481 (5.4)	1259 (19.5)	660 (20.4)	273 (21.2)	326 (17.0)
Alcohol daily consumption, mean (s.d.)	1.97 (2.17)	1.58 (1.70)	2.08 (2.25)	2.22 (2.51)	2.62 (2.33)	2.70 (2.39)	2.72 (2.29)	2.41 (2.26)
Education, n (%)								
High school graduate, GED or equivalent	15615 (24.6)	3898 (23.2)	9430 (25.0)	2287 (25.7)	1617 (21.9)	663 (19.3)	341 (24.1)	613 (24.2)
Some college or AA degree	11759 (18.5)	2877 (17.1)	7205 (19.1)	1677 (18.9)	2252 (30.5)	1067 (31.0)	411 (29.1)	774 (30.5)
College graduate	28325 (44.6)	8592 (51.1)	16429 (43.5)	3304 (37.2)	1921 (26.0)	1077 (31.3)	365 (25.8)	479 (18.9)
Other	7753 (12.2)	1447 (8.6)	4683 (12.4)	1623 (18.3)	1602 (21.7)	636 (18.5)	296 (20.9)	670 (26.4)
Fruit and vegetable consumption,	8.04 (4.35)	8.13 (4.46)	7.96 (4.29)	8.19 (4.40)	4.61 (3.36)	4.71 (3.53)	4.60 (3.24)	4.48 (3.17)

mean (s.d.), servings/day								
Previous CVD, n (%)	5199 (8.2)	903 (5.4)	2923 (7.7)	1373 (15.4)	827 (11.2)	138 (4.0)	80 (5.7)	609 (24.2)
Family history of CVD, n (%)	34776 (54.8)	8235 (49.0)	20816 (55.1)	5725 (64.4)	837 (11.6)	316 (9.4)	139 (10.1)	382 (15.4)
Non-exerciser, n (%)	20095 (31.7)	4545 (27.0)	12080 (32.0)	3470 (39.0)	3744 (50.6)	1493 (43.3)	717 (50.7)	1534 (60.4)
Sleep, mean (s.d.), minutes/day	442.38 (90.04)	444.76 (92.59)	442.10 (90.37)	439.09 (83.33)	380.91 (124.45)	394.35 (119.28)	371.41 (124.65)	367.96 (129.31)
HbA1C, mean (s.d.), %	5.38 (0.50)	5.28 (0.37)	5.37 (0.48)	5.58 (0.67)	5.80 (1.14)	5.52 (0.88)	5.82 (1.20)	6.18 (1.30)
HDL, mean (s.d.), mg/dL	57.67 (14.84)	60.09 (14.66)	57.50 (14.79)	53.87 (14.51)	52.47 (15.53)	53.05 (14.83)	52.50 (17.17)	51.65 (15.47)
LDL, mean (s.d.), mg/dL	138.08 (32.60)	133.62 (30.93)	142.46 (32.28)	127.94 (33.57)	113.20 (35.47)	114.08 (34.05)	118.57 (35.46)	109.51 (37.02)
triglyceride, mean (s.d.), mg/dL	145.93 (84.77)	122.16 (69.78)	152.11 (87.49)	164.66 (89.40)	127.58 (120.99)	117.59 (137.19)	134.05 (99.60)	138.44 (103.67)
SBP, mean (s.d.), mmHg	138.04 (18.32)	117.65 (7.25)	144.81 (14.81)	147.89 (16.93)	123.87 (16.98)	112.58 (8.75)	135.73 (12.87)	132.58 (17.80)

DBP, mean (s.d.), mmHg	81.53 (10.07)	71.20 (5.05)	85.20 (8.52)	85.45 (9.62)	70.37 (11.10)	66.84 (8.03)	78.21 (10.84)	70.78 (12.44)
Waist circumference, mean (s.d.), cm	88.11 (12.95)	82.10 (11.00)	89.16 (12.49)	95.05 (13.54)	99.70 (16.35)	94.69 (14.81)	101.23 (16.02)	105.88 (16.32)
Body mass index, mean (s.d.), kg/m²	26.63 (4.49)	24.75 (3.57)	26.93 (4.37)	28.91 (5.13)	29.20 (6.97)	27.57 (6.03)	29.57 (7.01)	31.24 (7.57)
CVD mortality, n (%)	478 (0.8)	50 (0.3)	292 (0.8)	136 (1.8)	233 (3.1)	40 (1.2)	27 (1.9)	166 (6.5)
Daily MVPA duration, mean (s.d.), minutes/day	38.41 (24.76)	41.03 (25.08)	38.70 (24.83)	32.23 (22.76)	19.75 (17.37)	24.17 (17.50)	22.13 (17.88)	12.42 (14.22)

Abbreviations:
AA, Associate's degree;
GED, General Educational Development;
HDL, high-density lipoprotein cholesterol;
LDL, low-density lipoprotein cholesterol;

Supplementary Table 3: Number of all-cause mortality events by moderate-to-vigorous physical activity tertiles within hypertension subgroups in UK Biobank and NHANES

	UKBB medicated HTN	*UKBB unmedicated HTN*	*UKBB normotensive*	*NHANES medicated HTN*	*NHANES unmedicated HTN*	*NHANES normotensive*
Overall	367	1,032	259	260	78	78
MVPA Tertiles						
Low	166	432	116	181	56	54
Intermediate	105	337	83	53	13	12
High	96	263	60	26	9	12

Values represent the total number of all-cause mortality events observed during follow-up in each MVPA tertile, stratified by hypertension status.